XCUR Stock Overview
An early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Exicure, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.47 |
| 52 Week High | US$1.50 |
| 52 Week Low | US$0.36 |
| Beta | 1.23 |
| 1 Month Change | -13.82% |
| 3 Month Change | -21.53% |
| 1 Year Change | -45.91% |
| 3 Year Change | -99.06% |
| 5 Year Change | -99.45% |
| Change since IPO | -99.50% |
Recent News & Updates
Recent updates
Little Excitement Around Exicure, Inc.'s (NASDAQ:XCUR) Revenues As Shares Take 25% Pounding
Aug 29
Exicure to get $5.4M equity financing, reduce workforce & end R&D, preclinical activities
Sep 26Exicure Q2 GAAP loss per share narrows, revenue up
Aug 15Exicure regains compliance with Nasdaq's minimum bid price requirement
Jul 20Exicure slides 31% as it implements reverse-stock-split to get back Nasdaq compliance
Jun 29Does Exicure (NASDAQ:XCUR) Have A Healthy Balance Sheet?
Aug 25Does Exicure (NASDAQ:XCUR) Have A Healthy Balance Sheet?
Mar 10A Look At Exicure's (NASDAQ:XCUR) Share Price Returns
Jan 13Exicure announces issuance of two new U.S. patents, and new patent allowance
Dec 21How Much Of Exicure, Inc. (NASDAQ:XCUR) Do Institutions Own?
Dec 15Exicure (XCUR) Investor Presentation - Slideshow
Nov 18Shareholder Returns
| XCUR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -7.0% | 0.7% | 1.2% |
| 1Y | -45.9% | 5.0% | 27.7% |
Return vs Industry: XCUR underperformed the US Biotechs industry which returned 5% over the past year.
Return vs Market: XCUR underperformed the US Market which returned 27.7% over the past year.
Price Volatility
| XCUR volatility | |
|---|---|
| XCUR Average Weekly Movement | 8.1% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: XCUR's share price has been volatile over the past 3 months.
Volatility Over Time: XCUR's weekly volatility has decreased from 13% to 8% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 7 | Paul Kang | www.exicuretx.com |
Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company’s preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology.
Exicure, Inc. Fundamentals Summary
| XCUR fundamental statistics | |
|---|---|
| Market cap | US$4.10m |
| Earnings (TTM) | US$2.97m |
| Revenue (TTM) | US$21.77m |
1.4x
P/E Ratio0.2x
P/S RatioIs XCUR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XCUR income statement (TTM) | |
|---|---|
| Revenue | US$21.77m |
| Cost of Revenue | US$16.06m |
| Gross Profit | US$5.72m |
| Other Expenses | US$2.75m |
| Earnings | US$2.97m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.34 |
| Gross Margin | 26.27% |
| Net Profit Margin | 13.64% |
| Debt/Equity Ratio | 0% |
How did XCUR perform over the long term?
See historical performance and comparison